Download or read book ASTATINE 211 RADIOCHEMISTRY written by and published by . This book was released on 2012 with total page 11 pages. Available in PDF, EPUB and Kindle. Book excerpt: Targeted radionuclide therapy is emerging as a viable approach for cancer treatment because of its potential for delivering curative doses of radiation to malignant cell populations while sparing normal tissues. Alpha particles such as those emitted by 211At are particularly attractive for this purpose because of their short path length in tissue and high energy, making them highly effective in killing cancer cells. The current impact of targeted radiotherapy in the clinical domain remains limited despite the fact that in many cases, potentially useful molecular targets and labeled compounds have already been identified. Unfortunately, putting these concepts into practice has been impeded by limitations in radiochemistry methodologies. A critical problem is that the synthesis of therapeutic radiopharmaceuticals provides additional challenges in comparison to diagnostic reagents because of the need to perform radio-synthesis at high levels of radioactivity. This is particularly important for?-particle emitters such as 211At because they deposit large amounts of energy in a highly focal manner. The overall objective of this project is to develop convenient and reproducible radiochemical methodologies for the radiohalogenation of molecules with the?-particle emitter 211At at the radioactivity levels needed for clinical studies. Our goal is to address two problems in astatine radiochemistry: First, a well known characteristic of 211At chemistry is that yields for electrophilic astatination reactions decline as the time interval after radionuclide isolation from the cyclotron target increases. This is a critical problem that must be addressed if cyclotrons are to be able to efficiently supply 211At to remote users. And second, when the preparation of high levels of 211At-labeled compounds is attempted, the radiochemical yields can be considerably lower than those encountered at tracer dose. For these reasons, clinical evaluation of promising 211At-labeled targeted radiotherapeutics currently is a daunting task. Our central hypothesis is that improvements in 211At radiochemistry are critically dependent on gaining an understanding of and compensating for the effects of radiolysis induced by 211At?-particles. Because of the widespread interest in labeling antibodies, antibody fragments and peptides with 211At, our proposed work plan will initially focus on reagents that we have developed for this purpose. Part of our strategy is the use of synthetic precursors immobilized on polymeric resins or perfluorous and triarylphosphonium supports. Their use could eliminate the need for a purification step to separate unreacted tin precursor from labeled product and hopefully provide a simple kit technology that could be utilized at other institutions. The specific aims of this project are: (1) To optimze methods for 211At production and isolation of 211At from cyclotron targets; (2) To develop convenient and reproducible methodologies for high activity level and high specific activity radiohalogenation of biomolecules with 211At; (3) to develop a procedure for extending the shelf-life of 211At beyond a few hours so that this radionuclide can be utilized at centers remote from its site of production; and (4) to work out high activity level synthesis methods for utilizing support immobilized tin precursors for 211At labeling. If we are successful in achieving our goals, the radiochemical methodologies that are developed could greatly facilitate the use of 211At-labeled targeted cancer therapeutics in patients, even at institutions that are distant from the few sites currently available for 211At production.

Download or read book Production of Astatine 211 at the Duke University Medical Center for Its Regional Distribution written by and published by . This book was released on 2016 with total page 13 pages. Available in PDF, EPUB and Kindle. Book excerpt: Systemic targeted radiation therapy and radioimmunotherapy continue to be important tools in the treatment of certain cancers. Because of their high energy and short path length, alpha particle emitters such as 211At are more effective than either external beam x- ray or in vivo beta radiation in delivering potentially curative doses of radiation. The limited clinical trials that have been conducted to date have yielded encouraging responses in some patients, e.g., malignant brain tumors. In order to escalate the additional necessary research and development in radiochemistry, radiobiology and efficacy evaluation of alpha particle radiotherapeutics, it is universally agreed that access to an affordable, reliable supply of 211At is warranted. In conjunction with the Department of Energy's intent to enhance stable and radioactive isotope availability for research applications, it is the primary objective of this project to improve 211At production and purification capabilities at Duke so that this radionuclide can be supplied to researchers at other institutions throughout the US. The most widely used 211At production method involves the [alpha],2n reaction on Bismuth using a cyclotron with beams d"28 MeV. Yields can be enhanced with use of an internal target that allows for a higher alpha fluence plus efficient heat dissipation in the target. Both of these items are in place at Duke; however, in order to support production for multi-institutional use, irradiation campaigns in excess of 50 æAp and four hours duration will be needed. Further, post-irradiation processing equipment is lacking that will enable the distribution process. Financial support is sought for i) a shielded, ventilated processing/containment hood; ii) development of a post-irradiation target retrieval system; iii) fabrication of a 211At distillation and recovery module and iv) a performance review and, where needed, an enhancement of seven major subsystems that comprise the CS-30 Cyclotron. With these modifications in place, routine production of e"00 mCi of At-211 should be readily achievable, given our methodological development of At-211 target preparation, internal target irradiation and dry distillation to recover the radionuclide.

Download or read book Advancing Nuclear Medicine Through Innovation written by National Research Council and published by National Academies Press. This book was released on 2007-09-11 with total page 173 pages. Available in PDF, EPUB and Kindle. Book excerpt: Nearly 20 million nuclear medicine procedures are carried out each year in the United States alone to diagnose and treat cancers, cardiovascular disease, and certain neurological disorders. Many of the advancements in nuclear medicine have been the result of research investments made during the past 50 years where these procedures are now a routine part of clinical care. Although nuclear medicine plays an important role in biomedical research and disease management, its promise is only beginning to be realized. Advancing Nuclear Medicine Through Innovation highlights the exciting emerging opportunities in nuclear medicine, which include assessing the efficacy of new drugs in development, individualizing treatment to the patient, and understanding the biology of human diseases. Health care and pharmaceutical professionals will be most interested in this book's examination of the challenges the field faces and its recommendations for ways to reduce these impediments.

Download or read book Astatine 211 and Iodine Conjugates written by Sture Lindegren and published by . This book was released on 2002 with total page 46 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Handbook of Radiopharmaceuticals written by Michael J. Welch and published by John Wiley & Sons. This book was released on 2003-01-17 with total page 872 pages. Available in PDF, EPUB and Kindle. Book excerpt: A comprehensive, authoritative and up-to-date reference for the newcomer to radiopharmaceuticals and those already in the field. Radiopharmaceuticals are used to detect and characterise disease processes, or normal biological function, in living cells, animals or humans. Used as tracer molecules, they map the distribution, uptake and metabolism of the molecule in clinical studies, basic research or applied research. The area of radiopharmaceuticals is expanding rapidly. The number of PET centers in the world is increasing at 20% per year, and many drug companies are utilising PET and other forms of radiopharmaceutical imaging to evaluate products. * Readers will find coverage on a number of important topics such as radionuclide production, PET and drug development, and regulations * Explains how to use radiopharmaceuticals for the diagnosis and therapy of cancer and other diseases * The editors and a majority of the contributors are from the United States

Download or read book Targeted Radionuclide Therapy written by Tod W. Speer and published by Lippincott Williams & Wilkins. This book was released on 2012-03-28 with total page 564 pages. Available in PDF, EPUB and Kindle. Book excerpt: Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank.

Download or read book The Production and Isolation of Astatine 211 for Biological Studies written by Marshall W. Parrott and published by . This book was released on 1955 with total page 10 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Production of the Alpha particle Emitting Radionuclide Astatine 211 at the Texas A M Cyclotron Institute written by Viharkumar Bhakta and published by . This book was released on 2011 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Chemical Properties of Astatine I written by Gordon Lee Johnson and published by . This book was released on 1948 with total page 20 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book The Radiochemistry of Astatine written by Evan H. Appelman and published by . This book was released on 1960 with total page 38 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book Radiopharmaceutical Chemistry written by Jason S. Lewis and published by Springer. This book was released on 2019-04-02 with total page 648 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is a comprehensive guide to radiopharmaceutical chemistry. The stunning clinical successes of nuclear imaging and targeted radiotherapy have resulted in rapid growth in the field of radiopharmaceutical chemistry, an essential component of nuclear medicine and radiology. However, at this point, interest in the field outpaces the academic and educational infrastructure needed to train radiopharmaceutical chemists. For example, the vast majority of texts that address radiopharmaceutical chemistry do so only peripherally, focusing instead on nuclear chemistry (i.e. nuclear reactions in reactors), heavy element radiochemistry (i.e. the decomposition of radioactive waste), or solely on the clinical applications of radiopharmaceuticals (e.g. the use of PET tracers in oncology). This text fills that gap by focusing on the chemistry of radiopharmaceuticals, with key coverage of how that knowledge translates to the development of diagnostic and therapeutic radiopharmaceuticals for the clinic. The text is divided into three overarching sections: First Principles, Radiochemistry, and Special Topics. The first is a general overview covering fundamental and broad issues like “The Production of Radionuclides” and “Basics of Radiochemistry”. The second section is the main focus of the book. In this section, each chapter’s author will delve much deeper into the subject matter, covering both well established and state-of-the-art techniques in radiopharmaceutical chemistry. This section will be divided according to radionuclide and will include chapters on radiolabeling methods using all of the common nuclides employed in radiopharmaceuticals, including four chapters on the ubiquitously used fluorine-18 and a “Best of the Rest” chapter to cover emerging radionuclides. Finally, the third section of the book is dedicated to special topics with important information for radiochemists, including “Bioconjugation Methods,” “Click Chemistry in Radiochemistry”, and “Radiochemical Instrumentation.” This is an ideal educational guide for nuclear medicine physicians, radiologists, and radiopharmaceutical chemists, as well as residents and trainees in all of these areas.

Download or read book 211At and 90Y written by H. E. Sims and published by . This book was released on 1986 with total page 8 pages. Available in PDF, EPUB and Kindle. Book excerpt:

Download or read book New Technologies for At 211 Targeted Alpha therapy Research Using Rn 211 and At 209 written by Jason Raymond Crawford and published by . This book was released on 2016 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: The most promising applications for targeted alpha-therapy with astatine-211 (At-211) include treatments of disseminated microscopic disease, the major medical problem for cancer treatment. The primary advantages of targeted alpha-therapy with At-211 are that the alpha-particle radiation is densely ionizing, translating to high relative biological effectiveness (RBE), and short-range, minimizing damage to surrounding healthy tissues. In addition, theranostic imaging with I-123 surrogates has shown promise for developing new therapies with At-211 and translating them to the clinic. Currently, Canada does not have a way of producing At-211 by conventional methods because it lacks alpha-particle accelerators with necessary beam energy and intensity. The work presented here was aimed at studying the Rn-211/At-211 generator system as an alternative production strategy by leveraging TRIUMF's ability to produce rare isotopes. Recognizing that TRIUMF provided production opportunities for a variety of astatine isotopes, this work also originally hypothesized and evaluated the use of At-209 as a novel isotope for preclinical Single Photon Emission Computed Tomography (SPECT) with applications to At-211 therapy research. At TRIUMF's Isotope Separator and Accelerator (ISAC) facility, mass separated ion beams of short?-lived francium isotopes were implanted into NaCl targets where Rn-211 or At-209 were produced by radioactive decay, in situ. This effort required methodological developments for safely relocating the implanted radioactivity to the radiochemistry laboratory for recovery in solution. For multiple production runs, Rn-211 was quantitatively transferred from solid NaCl to solution (dodecane) from which At-211 was efficiently extracted and evaluated for clinical applicability. This validated the use of dodecane for capturing Rn-211 as an elegant approach to storing and shipping Rn-211/At-211 in the future. Po-207 contamination (also produced by Rn-211 decay) was removed using a granular tellurium (Te) column before proceeding with biomolecule labelling. Although the produced quantities were small, the pure At-211 samples demonstrated these efforts to have a clear path of translation to animal studies. For the first time in history, SPECT/CT was evaluated for measuring At-209 radioactivity distributions using high energy collimation. The spectrum detected for At-209 by the SPECT camera presented several photopeaks (energy windows) for reconstruction. The 77-90 Po X?-ray photopeak reconstructions were found to provide the best images overall, in terms of resolution/contrast and uniformity. Collectively, these experiments helped establish guidelines for determining the optimal injected radioactivity, depending on scan parameters. Moreover, At-209-based SPECT demonstrated potential for pursuing image-?based dosimetry in mouse tumour models, in the future. Simultaneous SPECT imaging with At-209 and I-123 was demonstrated to be feasible, supporting the future evaluation of At-209 for studying/validating I-123 surrogates for clinical image-based At-211 dosimetry. This work also pursued a novel strategy for labelling cancer targeting peptides with At-211, using octreotate (TATE, a somatostatin analogue for targeting tumour cells, mostly neuroendocrine tumours) prepared with or without N-terminus PEGylation (PEG2), followed by conjugation with a closo-decaborate linking moiety (B10) for attaching At-211. Binding affinity and in vivo biodistributions for the modified peptides were determined using iodine surrogates. The results indicated that B10-PEG2-TATE retained target binding affinity but that the labelling reaction with iodine degraded this binding affinity significantly, and although having high in vivo stability, no I-123-B10-PEG2-TATE tumour uptake was observed by SPECT in a mouse tumour model positive for the somatostatin receptor (sstr2a). This suggested that further improvements are required for labelling.A new method for producing At-211 at TRIUMF is established, and At-209-?based SPECT imaging is now demonstrated as a new preclinical technology to measure astatine biodistributions in vivo for developing new radiopharmaceuticals with At-211. Combined with the theranostic peptide labelling efforts with iodine, these efforts provide a foundation for future endeavours with At-211-?based alpha-therapy at TRIUMF. All procedures were performed safely and rapidly, suitable for preclinical evaluations. All animal studies received institutional ethics approval from the University of British Columbia (UBC).

Download or read book Handbook of Nuclear Chemistry written by Attila Vértes and published by Springer Science & Business Media. This book was released on 2003 with total page 422 pages. Available in PDF, EPUB and Kindle. Book excerpt: Impressive in its overall size and scope, this five-volume reference work provides researchers with the tools to push them into the forefront of the latest research. The Handbook covers all of the chemical aspects of nuclear science starting from the physical basics and including such diverse areas as the chemistry of transactinides and exotic atoms as well as radioactive waste management and radiopharmaceutical chemistry relevant to nuclear medicine. The nuclear methods of the investigation of chemical structure also receive ample space and attention. The international team of authors consists of 77 world-renowned experts - nuclear chemists, radiopharmaceutical chemists and physicists - from Austria, Belgium, Germany, Great Britain, Hungary, Holland, Japan, Russia, Sweden, Switzerland and the United States. The Handbook is an invaluable reference for nuclear scientists, biologists, chemists, physicists, physicians practicing nuclear medicine, graduate students and teachers - virtually all who are involved in the chemical and radiopharmaceutical aspects of nuclear science. The Handbook also provides for further reading through its rich selection of references.

Download or read book Contamination of Water written by Arif Ahamad and published by Elsevier. This book was released on 2021-08-06 with total page 614 pages. Available in PDF, EPUB and Kindle. Book excerpt: Water containing significant amounts of inorganic and organic contaminants can have serious environmental consequences and serious health implications when ingested. Contamination of Water: Health Risk Assessment and Treatment Strategies takes an interconnected look at the various pollutants, the source of contamination, the effects of contamination on aquatic ecosystems and human health, and what the potential mitigation strategies are. This book is organized into three sections. The first section examines the sources of potential contamination. This includes considering the current scenario of heavy metal and pesticide contamination in water as well as the regions impacted due to industrialization, mining, or urbanization. The second section goes on to discuss water contamination and health risks caused by toxic elements, radiological contaminants, microplastics and nanoparticles, and pharmaceutical and personal care products. This book concludes with a section exploring efficient low-cost treatment technologies and remediation strategies that remove toxic pollutants from water. Contamination of Water incorporates both theoretical and practical information that will be useful for researchers, professors, graduate students, and professionals working on water contamination, environmental and health impacts, and the management and treatment of water resources. Provides practical case studies of various types and sources of contamination Discusses inorganic and organic contaminants and their impact on human health Evaluates effective water treatment and remediation technologies to remove toxins from water and minimize risk

Download or read book Cyclotron Produced Radionuclides written by International Atomic Energy Agency and published by . This book was released on 2009 with total page 266 pages. Available in PDF, EPUB and Kindle. Book excerpt: Application of radioisotopes has shown significant growth in the past decade, and a major factor contributing towards this growth is the availability of a large number of cyclotrons dedicated to the production of radioisotopes for medical applications. Although there are many articles in journals on cyclotrons and their use for radioisotope production, there is no single source of information for beginners on radioisotope production using cyclotrons. This publication attempts to address this deficiency. Its contains chapters on accelerator technology, theoretical considerations of nuclear reactions, the technology behind targetry, techniques on preparation of targets, irradiation of targets under high beam currents, target processing and target recovery.

Download or read book Final Report for Grant Entitled Production of Astatine 211 for U S Investigators written by and published by . This book was released on 2012 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Alpha-particle emitting radionuclides hold great promise in the therapy of cancer, but few alpha-emitters are available to investigators to evaluate. Of the alpha-emitters that have properties amenable for use in humans, 211At is of particular interest as it does not have alpha-emitting daughter radionuclides. Thus, there is a high interest in having a source of 211At for sale to investigators in the US. Production of 211At is accomplished on a cyclotron using an alpha-particle beam irradiation of bismuth metal. Unfortunately, there are few cyclotrons available that can produce an alpha particle beam for that production. The University of Washington has a cyclotron, one of three in the U.S., that is currently producing 211At. In the proposed studies, the things necessary for production and shipment of 211At to other investigators will be put into place at UW. Of major importance is the efficient production and isolation of 211At in a form that can be readily used by other investigators. In the studies, production of 211At on the UW cyclotron will be optimized by determining the best beam energy and the highest beam current to maximize 211At production. As it would be very difficult for most investigators to isolate the 211At from the irradiated target, the 211At-isolation process will be optimized and automated to more safely and efficiently obtain the 211At for shipment. Additional tasks to make the 211At available for distribution include obtaining appropriate shipping vials and containers, putting into place the requisite standard operating procedures for Radiation Safety compliance at the levels of 211At activity to be produced / shipped, and working with the Department of Energy, Isotope Development and Production for Research and Applications Program, to take orders, make shipments and be reimbursed for costs of production and shipment.